Company intelligence / Profile preview
Bionovis
- Ownership
- Private
- Employees
- ~350
- Development stage
- Other
Overview
Bionovis has established itself as a pioneer in Brazil for the production and commercialization of biological and biosimilar medicines. The company has impacted over one million lives and sold more than thirteen million medicines across Brazil. It operates at commercial scale with several products already serving patients through public health channels such as the Ministry of Health. Its pipeline includes monoclonal antibodies like infliximab for autoimmune diseases. The company continues to expand its portfolio via technology transfer partnerships with global pharmaceutical leaders. Clinical results are not detailed publicly but commercial supply to national health systems indicates regulatory approval for marketed products.
- Therapeutic areas
- Immunology
- Modalities
- Monoclonal antibodies (mAbs)Therapeutic proteinsBiosimilarsBiobetters
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Bionovis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bionovis.